Display options
Cite
Elers J, Strandbygaard U, Pedersen L, et al. Daily use of salmeterol causes tolerance to bronchodilation with terbutaline in asthmatic subjects. Open Respir Med J. 2010;4:48-50doi: 10.2174/1874306401004010048.
Elers, J., Strandbygaard, U., Pedersen, L., & Backer, V. (2010). Daily use of salmeterol causes tolerance to bronchodilation with terbutaline in asthmatic subjects. The open respiratory medicine journal, 448-50. https://doi.org/10.2174/1874306401004010048
Elers, Jimmi, et al. "Daily use of salmeterol causes tolerance to bronchodilation with terbutaline in asthmatic subjects." The open respiratory medicine journal vol. 4 (2010): 48-50. doi: https://doi.org/10.2174/1874306401004010048
Elers J, Strandbygaard U, Pedersen L, Backer V. Daily use of salmeterol causes tolerance to bronchodilation with terbutaline in asthmatic subjects. Open Respir Med J. 2010 Apr 21;4:48-50. doi: 10.2174/1874306401004010048. PMID: 20556208; PMCID: PMC2885602.
Copy Download .nbib Format: NLM
Share it on

Open Respir Med J. 2010 Apr 21;4:48-50. doi: 10.2174/1874306401004010048.

Daily use of salmeterol causes tolerance to bronchodilation with terbutaline in asthmatic subjects.

The open respiratory medicine journal

Jimmi Elers, Ulla Strandbygaard, Lars Pedersen, Vibeke Backer

Affiliations

  1. Respiratory and Allergy Research Unit, Bispebjerg Hospital, Copenhagen, Denmark.

PMID: 20556208 PMCID: PMC2885602 DOI: 10.2174/1874306401004010048

Abstract

BACKGROUND: The purpose was to assess tolerance to terbutaline after daily use of long-acting beta2- agonist (LABA) and further to evaluate two designs of reversibility test widely used in research and clinic in order to demonstrate tolerance.

METHODS: Twenty-eight asthmatics were given daily LABA in 12 weeks and were randomized to challenge test and either conventional reversibility test with 2 puffs terbutaline or reversibility test with refracted doses (1 puff) every 5 min, total 4 puffs. FEV(1) was measured pre-challenge, post-challenge, during and after reversibility test. All subjects had 3 visits: baseline, after 4 weeks and after 12 weeks of LABA treatment. All subjects were non-smokers, aged 18-45 years and had a positive methacholine challenge.

RESULTS: The analyses showed a significant fall in reversibility after 4 and 12 weeks of LABA treatment (p=0.001) in the group with the conventional reversibility test. The group with reversibility test using refracted doses also showed a significant fall in reversibility after 4 weeks of LABA treatment (p=0.017) followed by a similar trend after 12 weeks (p=0.054), however, we experienced an interfering number of dropouts at the last visit.

CONCLUSION: The bronchodilator response to terbutaline was significantly reduced in asthmatic subjects using daily LABA. The tolerance develops rapidly and is present after 4 weeks of treatment. Our study showed that both the conventional reversibility test and the reversibility test with refracted doses, combined with methacholine challenge is able to demonstrate tolerance to bronchodilator after daily use of LABA.

Keywords: Tolerance; asthma.; bronchodilator; tachyphylaxis; β-2-agonist

References

  1. Respir Med. 2005 May;99(5):566-71 - PubMed
  2. Eur Respir J. 1999 Oct;14(4):902-7 - PubMed
  3. BioDrugs. 2001;15(1):11-24 - PubMed
  4. Am J Respir Crit Care Med. 2004 Oct 15;170(8):836-44 - PubMed
  5. Respir Res. 2005 Sep 16;6:107 - PubMed
  6. N Engl J Med. 1997 Nov 13;337(20):1405-11 - PubMed
  7. JAMA. 2001 May 23-30;285(20):2583-93 - PubMed
  8. Eur Respir J. 2008 Jan;31(1):143-78 - PubMed
  9. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD005535 - PubMed

Publication Types